Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic profile of urinary extracellular vesicles from rats with lithium-induced nephrogenic diabetes insipidus

ABSTRACT: Bipolar disorder is a chronic psychiatric disorder characterized by recurrent episodes of mania and depression affecting more than 0.5% of the world’s population. Lithium (Li) is the gold-standard treatment for bipolar disorder and treatment-resistant unipolar depression due to its potent effects on preventing both manic and depressive episode. Patients who are taking Li for more than 10-20 years are at risk of chronic kidney disease, which ultimately can lead to end-stage renal disease, hemodialysis, kidney transplantation, and mortality. The Li-induced nephropathy includes interstitial fibrosis, microcysts originating from the distal tubule and the collecting duct, glomerulosclerosis, and tubular atrophy of the proximal tubule as evidenced in human renal biopsies and animal studies. Therefore, the purpose of the present study was to examine using mass spectrometry whether the effects of Li treatment for 2 or 4-weeks on rat kidney proteins are reflected in urinary extracellular vesicles (uEVs).

INSTRUMENT(S):

ORGANISM(S): Rattus Norvegicus (rat)

TISSUE(S): Urine

SUBMITTER: Qi Wu

LAB HEAD: Qi Wu

PROVIDER: PXD075285 | Pride | 2026-06-30

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	TMT_set1.msf	Msf
	TMT_set1_C_fraction1_01.raw	Raw
	TMT_set1_C_fraction1_01_20220102030703.raw	Raw
	TMT_set1_C_fraction1_01_20220102072102.raw	Raw
	TMT_set1_C_fraction2_01.raw	Raw

Items per page:

1 - 5 of 51

Similar Datasets

Gene-expression differences in peripheral blood between lithium responders and non-responders in the “Lithium Treatment -Moderate dose Use Study” (LiTMUS)

Project description:Analysis of gene-expression changes in treatment responders vs non-responders to two different treatments among subjectrs participating in LiTMUS. Results provide information on pathways that may be involved in the clinical response to Lithium in patients with bipolar disorder. Total RNA isolated from PAXgene blood RNA tubes from 60 subjects with bipolar disorder, randomized to 2 treatment groups (OPT, Li+OPT) at 2 time-points (baseline, 1 month after treatment)

2013-03-26 | E-GEOD-45484 | biostudies-arrayexpress

Peripheral blood gene-expression in depressed subjects with bipolar disorder vs healthy controls.

Project description:Analysis of gene-expression changes in depressed subjects with bipolar disorder compared to healthy controls. Results provide information on pathways that may be involved in the pathogenesis of bipolar depression. Total RNA isolated from PAXgene blood RNA tubes from 20 depressed subjects with bipolar disorder and 15 healthy controls.

2010-08-27 | E-GEOD-23848 | biostudies-arrayexpress

Molecular signatures of hyperexcitability and lithium responsiveness in bipolar disorder patient neurons provides alternative therapeutic strategies

Project description:Bipolar Disorder (BD) is a chronic psychiatric illness affecting ~3% of the global population. It is one of the top 10 causes of disability and mortality worldwide, largely due to high suicide, cardiovascular, and metabolic comorbidity. Typically, BD has life-long presentation characterized by alternations of extreme mania and depression, associated with psychosis and self-harm. Given the complex heritability and symptoms of BD, long term clinical management of some patients remains unsatisfactory. Thus, there is a major unmet need for new clinical treatment strategies and drug options to help these patients. Lithium (Li) remains the gold standard mood stabilizer and first-line treatment for manic/depressive episodes, reducing suicide and overall mortality rates. Two major questions stand out i) how Li is effective, and ii) why for only a subset of patients? To address this, we studied the biology and lithium effects in iPSC-derived neurons from people with a known clinical and genetic profile, comparing healthy individuals, BD Li-responders, and BD Li-non responders. We combined cell imaging, electrophysiology, biochemistry, , phosphoproteomic and whole transcriptome sequencing approaches to provide mechanistic insights and guide the search for BD biomarkers and Li responsiveness.

2025-07-04 | GSE236482 | GEO

Transcriptional profiling of monocytes of bipolar patients and controls

Project description:Bipolar disorder (BD) is a psychiatric disorder in which the core feature is pathological disturbance in mood ranging from extreme elation (mania) to severe depression. Study has shown an aberrant pro-inflammatory status of monocytes/macrophages in mood disorders. Therefore, this study aimed at studying the monocyte compartment in Bipolar Disorder, by transcription profiling of CD14+ monocytes in patients and controls.

2008-01-01 | E-MEXP-1275 | biostudies-arrayexpress

Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis

Project description:Nephropathic cystinosis is a severe monogenic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established renal proximal tubulopathy. Here, we developed a new therapeutic strategy by applying omics to expand our knowledge on the complexity of the disease and prioritize drug targets in cystinosis. We identified alpha-ketoglutarate as a potential metabolite to bridge cystinosin loss to autophagy, apoptosis and kidney proximal tubule impairment in cystinosis. This insight combined with a drug screen revealed a bicalutamide-cysteamine combination treatment as a novel dual-target pharmacological approach for the phenotypical correction of cystinotic kidney proximal tubule cells, patient-derived kidney tubuloids and cystinotic zebrafish.

2021-06-24 | MTBLS2538 | MetaboLights

MicroRNA expression data from lymphoblastoid cell lines from patients with bipolar disorder

Project description:Bipolar disorder (BD) (1% of the general population) is a major affective disorder characterized by recurrent manic and depressive episodes and associated with considerable burden and costs. Lithium (Li) is the first line treatment for relapse prevention in bipolar disorders with many patients who remain asymptomatic for several years (even decades). In addition, it is the only psychoactive drug that has demonstrated efficacy in suicide prevention. However a large proportion of patients is experiencing very high relapse rates (overall between 70 and 80% relapse, 2 years after a major episode). Li mechanism of action is rather complex and still not fully understood despite extensive studies. In order to explore potential lithium effects on global gene and miRNAs expression, we initiated a study in cell-lines from excellent responders (ER) and non-responders (NR) bipolar patients Briefly, long-term treatment response to lithium was evaluated using a validated scale “Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder” , also known as the Alda scale. In our sample we analyzed dichotomous phenotypes for lithium response: patients with total score (TS) higher or equal to 7, characterized as ER; and patients with TS lower than 2, characterized as NR according to the literature.

2017-07-04 | GSE93113 | GEO

Gene expression data from lymphoblastoid cell lines from patients with bipolar disorder

2017-07-04 | GSE93112 | GEO

Peripheral blood gene-expression in depressed subjects with bipolar disorder vs healthy controls.

2010-08-27 | GSE23848 | GEO

Signaling Mechanisms in Initiation of Lithium-Induced Nephrogenic Diabetes Insipidus

Project description:Lithium treatment is commonly used to treat bipolar disorder. However, this treatment disrupts kidney fuctionality. We used microdissected cortical collecting ducts to study proteomics and ultimately discover what changes occur in protein expression after 72-hr lithium treatment.

2019-07-01 | PXD010118 | Pride

Flcn and BHD renal tumorigenesis

Project description:Targeted disruption of Flcn in mouse kidney proximal tubule gives insights into human BHD renal tumorigenesis Mouse Tumor kidney tissue vs. normal kidney tissue

2014-07-28 | E-GEOD-49397 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data